Eva Querdel, Marina Reinsch, Liesa Castro, Deniz Köse, Andrea Bähr, Svenja Reich, Birgit Geertz, Bärbel Ulmer, Mirja Schulze, Marc D Lemoine, Tobias Krause, Marta Lemme, Jascha Sani, Aya Shibamiya, Tim Stüdemann, Maria Köhne, Constantin V von Bibra, Nadja Hornaschewitz, Simon Pecha, Yusuf Nejahsie, Ingra Mannhardt, Torsten Christ, Hermann Reichenspurner, Arne Hansen, Nikolai Klymiuk, M Krane, C Kupatt, Thomas Eschenhagen, Florian Weinberger
Background: Human engineered heart tissue (EHT) transplantation represents a potential regenerative strategy for heart failure patients and has been successful in preclinical models. Clinical application requires upscaling, adaptation to good manufacturing practices (GMP) and determination of the effective dose. Methods: Cardiomyocytes were differentiated from three different human induced pluripotent stem cell (hiPSC) lines including one reprogrammed under GMP conditions. Protocols for hiPSC expansion, cardiomyocyte differentiation and EHT generation were adapted to substances available in GMP quality...
March 2, 2021: Circulation